Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study ...
Under the Trump administration, the Securities and Exchange Commission is in the process of revamping its approach to the cost-benefit analysis it performs in support of its regulatory actions. These ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback